InMed Pharmaceuticals Inc 8-K, filed Jan 19, 2021
InMed Pharmaceuticals Inc. (MTRI)
About this 8-K
InMed Pharmaceuticals Inc filed this 8-K on January 19, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 19, 2021
INMED PHARMACEUTICALS INC.
(Exact Name of Company as Specified in Charter)
| British Columbia | 001-39685 | 98-1428279 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
InMed Pharmaceuticals Inc. Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada |
V6C 1B4 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Company’s telephone number, including area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common Shares, no par value | INM | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On January 19, 2021 the Company issued a press release announcing that that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
| Exhibit No. | Description | |
| 99.1 | News release, dated January 19, 2021 _ |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMED PHARMACEUTICALS INC. | ||
| Date: January 19, 2021 | By: | /s/ Bruce Colwill |
Bruce Colwill Chief Financial Officer | ||
2
Exhibit 99.1
|
TSX:IN NASDAQ:INM
Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com |
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
InMed’s Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers
Vancouver, BC – January 19, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe (“CDP Europe”). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg - Vice President, Chemistry, Manufacturing & Controls, Karen Long - Senior Director, Drug Development, and Prof. Mauro Maccarrone PhD - Scientific Advisor to InMed will all be featured as expert speakers at the event.
Mr. Michael Woudenberg will participate on a panel discussion on the topic of “Comparing Whole Plant & Synthetic Cannabinoids & Their Potential in Pharmaceuticals” which will cover topics including the availability of cannabinoids in both whole plant and synthetic systems, the biggest trade-off between plant-derived and synthetic compounds and comparing cost advantages in the short and long term.
Ms. Karen Long will participate on a panel discussion on the topic of “The Industry Approach to Gaining Drug Approval” to compare the differences in gaining drug approval around the world including a discussion of case studies.
In addition, Prof. Mauro Maccarrone, a member of InMed’s Scientific Advisory Board and Professor and Chair of Biochemistry, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy, will speak on the complexity of the endocannabinoid system while discussing the critical issues around endocannabinoid signaling regulation in a lecture entitled “Plant-Derived & Endogenous Cannabinoids: Naturally Different”.
“We are grateful for the opportunity to participate in the CDP Europe event as part of our ongoing commitment to being at the forefront of novel cannabinoid therapeutics and novel means of manufacturing them,” remarked Eric A. Adams, President and Chief Executive Officer of InMed. “InMed has made important strides in both its therapeutic development and manufacturing programs over the past year and that has reinforced our position as a leading innovator to speak on these key topics.”
For more information on the conference, please visit https://cdp-europe.com/.
About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (“CBN”) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.
Investor Contact: InMed Pharmaceuticals Inc. Brendan Payne, Director - Investor Relations T: +1.604.669.7207 E: info@inmedpharma.com |
Edison Group for InMed Pharmaceuticals: Joe Green/Laine Yonker T: +1.646.653.7030/+1.646.653.7035 E: jgreen@edisongroup.com lyonker@edisongroup.com |
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: presenting at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe; leading the way in the clinical development of cannabinol (CBN); developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.